Andrew Huberman retatrutide clips circulate widely, but there is no dedicated Huberman Lab episode — here's what he has actually said about GLP-1 drugs.
Andrew Huberman has not released a dedicated Huberman Lab episode on retatrutide. What circulates online is a mix of his broader commentary on GLP-1 drugs such as semaglutide and tirzepatide, short podcast clips, and secondhand summaries that get attributed to him. Retatrutide itself is an investigational drug that is not FDA-approved for any use in the United States.
What Andrew Huberman Has Said About GLP-1 Drugs
Huberman is a Stanford-trained neuroscientist and the host of Huberman Lab, not a prescribing physician. When he has discussed GLP-1 receptor agonists, he has generally treated them as legitimate pharmaceutical tools with real tradeoffs rather than as miracle drugs or moral failures.
Recurring themes in his GLP-1 conversations include:
- Lean mass loss. Rapid weight loss without resistance training and adequate protein can strip muscle along with fat.
- Appetite and nutrient intake. Eating less volume often means less protein, fiber, and micronutrients unless meals are planned deliberately.
- Lifestyle pairing. He consistently frames these drugs as an adjunct to training, sleep, and diet rather than a replacement for them.
- Medical supervision. Dosing, titration, and side-effect management belong with a clinician.
Retatrutide is a different molecule from semaglutide or tirzepatide, and it has not been the focus of a dedicated episode. That gap is exactly why so many people search for "andrew huberman retatrutide" and land on clip compilations instead of a primary source.
It is also worth separating podcast commentary from commerce. Questions about the andrew huberman peptide company usually trace back to his supplement partnerships, which sell sleep, focus, and fitness products — not GLP-1 drugs or research peptides. Huberman does not sell retatrutide, and no podcast host can prescribe it.
What Retatrutide Actually Is
Retatrutide (development code LY3437943) is an investigational triple agonist made by Eli Lilly. It activates three receptors at once: GLP-1, GIP, and glucagon. The glucagon arm is what separates it from tirzepatide, which is a dual GLP-1/GIP agonist.
In a phase 2 trial published in the New England Journal of Medicine in 2023, adults with obesity who received 12 mg weekly lost a mean of roughly 24% of their body weight over 48 weeks. That effect size is larger than what has been reported for semaglutide or tirzepatide in comparable trials.
Key facts to keep straight:
- Status: Not FDA-approved. Phase 3 trials (the TRIUMPH program) are still running.
- Route: Once-weekly subcutaneous injection in trials.
- Common side effects: Nausea, diarrhea, vomiting, constipation, and reduced appetite.
- Notable signal: Higher rates of dysesthesia, or altered skin sensation, were reported at higher doses.
- Availability: The FDA has warned that compounded and "research grade" retatrutide sold online is unapproved and potentially unsafe.
Why Chase Irons and Jay Campbell Show Up in These Searches
Searches for chase irons retatrutide and jay campbell retatrutide land in the same results as Huberman for a simple reason: all three are high-profile voices in the fitness, performance, and longevity space, and audiences treat their commentary as interchangeable.
Their angles differ, though, and that matters when you are weighing what you hear.
| Voice | Background | Typical retatrutide angle |
|---|---|---|
| Andrew Huberman | Neuroscientist; host of Huberman Lab | Broader GLP-1 science, lean mass, lifestyle pairing; no dedicated retatrutide episode |
| Chase Irons | Bodybuilding and PED commentator | Physique-focused talk on GLP-1s, dosing culture, and muscle retention |
| Jay Campbell | TRT and peptide advocate, author, podcaster | Hormone optimization framing, research peptides, and sourcing questions |
None of these three is running a clinical trial or prescribing retatrutide. Podcast content is commentary, not medical guidance, especially when a clip is being used to sell a product.
Reconstitution Questions That Follow the Podcasts
Because retatrutide is not commercially available, most practical questions people search for are about handling a lyophilized powder — how to mix retatrutide with bac water, what concentration that produces, and how long it stays usable. This is educational information only; unapproved peptides bought online carry unknown purity and sterility risks.
Concentration is simple arithmetic: total milligrams divided by milliliters of diluent.
| Vial size | Bacteriostatic water added | Resulting concentration |
|---|---|---|
| 10 mg | 1 mL | 10 mg/mL |
| 10 mg | 2 mL | 5 mg/mL |
| 12 mg | 1.2 mL | 10 mg/mL |
| 12 mg | 2.4 mL | 5 mg/mL |
More diluent makes small doses easier to measure accurately but means a larger injection volume. For a 10 mg vial, searches like how much bac water for 10 mg retatrutide typically resolve to 1–2 mL depending on the concentration you want.
Once reconstituted, refrigerate at 2–8°C and protect the vial from light. There is no official stability data for an unapproved drug, so the question of how long does retatrutide last after adding bac water does not have a regulatory answer; general peptide-handling guidance is roughly four to six weeks refrigerated, and any cloudiness, particles, or discoloration means discarding the vial.
How Retatrutide Compares With Other Fat-Loss Peptides
People who follow peptide podcasts often ask about aod 9604 vs retatrutide, and the honest comparison is lopsided. AOD 9604 is a fragment of human growth hormone studied for fat metabolism, and its weight-loss effects in trials have been modest. Retatrutide produced roughly 24% body weight reduction in phase 2, which is a different league entirely.
| Compound | Mechanism | Reported weight loss | Regulatory status |
|---|---|---|---|
| Retatrutide | GLP-1 + GIP + glucagon agonist | ~24% at 48 weeks (12 mg, phase 2) | Investigational |
| Tirzepatide | GLP-1 + GIP agonist | About 20% in trials | FDA-approved |
| Semaglutide | GLP-1 agonist | About 15% in trials | FDA-approved |
| AOD 9604 | hGH fragment 176-191 | Modest and inconsistent | Not FDA-approved for weight loss |
Muscle retention matters as much as the number on the scale. Whichever compound is in play, protein intake and resistance training are the levers that protect lean mass during rapid weight loss.
The Bottom Line on Huberman and Retatrutide
Andrew Huberman has discussed GLP-1 drugs in general terms, but he has not published a dedicated retatrutide episode, and no host's commentary substitutes for clinical trial data.
Retatrutide is not FDA-approved for human use in the United States. It is an investigational triple agonist with strong phase 2 weight-loss results and a real side-effect profile that includes gastrointestinal symptoms and dysesthesia.
If you are considering any GLP-1-class medication, talk with a licensed healthcare professional about approved options, dosing, and monitoring. If you are simply following the podcast conversation, check primary sources such as the published trial and FDA statements before acting on a clip.
Frequently Asked Questions
Has Andrew Huberman talked about retatrutide specifically?
There is no dedicated Huberman Lab episode on retatrutide as of this writing. Huberman has discussed GLP-1 receptor agonists broadly, including semaglutide and tirzepatide, and short clips from those conversations are often labeled as retatrutide content. Anyone citing a direct Huberman quote about retatrutide should be able to point to the original episode and timestamp.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational triple agonist from Eli Lilly and is not approved for any human use in the United States. Phase 3 trials are ongoing, and the FDA has warned that compounded or research-grade retatrutide sold online is unapproved and potentially unsafe.
How much weight did people lose on retatrutide in trials?
In a 2023 phase 2 trial published in the New England Journal of Medicine, adults with obesity who took 12 mg weekly lost a mean of about 24% of their body weight over 48 weeks. Individual results varied, and common side effects included nausea, diarrhea, vomiting, and constipation. Results from a trial are not a guarantee of what any one person will experience.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.